News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


SNO 2019: The Oncolytic Herpes Virus G47? May Lead to a Potential Cure of Malignant Glioma


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is a small study and needs to be replicated but this might be the biggest advance we have ever seen. They reported a 1 year survival rate of 92% in recurrent glioblastoma.  This is unheard of. Typically they expect 15% 1 year survival.    The survival curve (compared to historical controls) is on our website at https://forum.virtualtrials.org/forum/brain-tumor-research/122-g47-delta-results-available-on-17thnovember  and it is very impressive.

 Unfortunately it appears as if this is only available in Japan.  We need to get this to the USA.

The treatment is a third generation oncolytic herpes virus and it seems to work in all types of cancers that they tried.  The clinical trial was terminated early because it actually works,

 


Posted on: 11/25/2019

SNO 2019: The Oncolytic Herpes Virus G47? May Lead to a Potential Cure of Malignant Glioma

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740